Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Rivaroxaban for Thromboprophylaxis in Idiopathic Membranous Nephropathy
NCT07404436Phase 4Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rivaroxaban in idiopathic membranous nephropathy (IMN) (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Incidence of the primary efficacy endpoint (composite of pulmonary embolism, deep vein thrombosis, and lower-extremity deep vein thrombosis) at 6 months. Started Jan 2024; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT07404436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07404436.